Antibacterial activity of lactobacilli probiotics on clinical strains of Helicobacter pylori

Document Type: Original Article


Department of Microbiology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran


Objective(s): Treatment of Helicobacter pylori infection by common drugs may be associated with several problems such as antimicrobial resistance to commonly used antibiotics and side effects of employed drugs. Therefore, exploration of non-chemical compounds which are safer than chemical ones is becoming important as an alternative therapy. The purpose of this study was to evaluate the effects of lactic acid bacteria (LAB) against clinical strains of H. pylori.
Materials and Methods: Study of antibacterial effects of LAB against H. pylori strains included:  evaluation of LAB effects as well as its cell-free supernatant (CFS) to reduce the number of H. pylori, and to examine the effects of CFS to inhibit the urease activity of H. pylori. The anti-adhesion effect of LAB on adherence of H. pylori to epithelial cell line was also evaluated.
Results: Evaluation of the anti H. pylori effect of LAB depended on the strain of H. pylori and Lactobacillus. However, CFS of LAB reduced significantly the growth of all H. pylori strains. Also, urease activity of H. pylori strains was inhibited by CFS of LAB demonstrating that their organic acid may have a role in this inhibition. The significant anti-adhesion effect of LAB on adherence of H. pylori was also observed.
Conclusion: Presence of LAB and/or their CFS can reduce the count of H. pylori, inhibit the urease activity of H. pylori, and reduce adhesion of H. pylori to epithelial cell line. This may be important for the impact of H. pylori colonization in the host stomach.


Main Subjects

1. Gorbach SL. Probiotics and gastrointestinal health. Am J Gastroenterol 2000; 95: 2-4. 

2. Islam SU. Clinical Uses of Probiotics. Medicine (Baltimore) 2016 ;95:e2658.

3. Diaconu S, Predescu A, Moldoveanu A, Pop CS, Fierbințeanu-Braticevici C. Helicobacter pylori infection: old and new. J Med Life 2017;10:112-117.

4. Figura N, Marano L, Moretti E, Ponzetto A. Helicobacter pylori infection and gastric carcinoma: Not all the strains and patients are alike. World J Gastrointest Oncol 2016;8:40-54.

5. Backert S, Neddermann M, Maubach G, Naumann M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2016; 1:19-25.

6. De Francesco V, Bellesia A, Ridola L, Manta R, Zullo A. First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines. Ann Gastroenterol  2017;30:373-379.

7. Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter  pylori. World Gastroenterol 2014 ;20:9898-98911.

8. Smith SM, OMorain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol 2014; 20: 9912–9921.

9. Ayala G, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014; 20: 1450–1469.

10. Kasra -Kermanshahi R, Rezai P. Probiotics and Prebiotics in medicine and dentistry. Iran J Med Microbiol 2015; 9: 1-13.

11. McNulty C, Owen R, Tompkins D, Hawtin P, McColl K, Price A, et al. Helicobacter pylori susceptibility testing by disc diffusion. J Antimicrob Chemother 2002; 49:601-609.

12. Falsafi T, Mobasheri F, Nariman F &  Najafi M. Susceptibilities to Different Antibiotics of  Helicobacter pylori Strains Isolated from Patients at the Pediatric Medical Center of Tehran, Iran. J Clin Microbiol 2004, 42:387–389.

13. Mishra KK, Srivastava S, Grag A, Ayyagari A. Antibiotic Susceptibility of Helicobacter pylori Clinical Isolates: Comparative Evaluation of Disk-Diffusion and E-Test Methods. Curr Microbiol 2006; 53: 329–334.

14. Wu H, Shi XD, Wang HT, Liu JX. Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxicillin. J Antimicrob Chemother  2000; 46:121-123.

15. Torre J, Camorlinga-Ponce G, Pérez-Pérez  A, Madrazo M, Dehesa G, Gonzales V, et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin  Microbiol  2001; 39:22677-22680.

16. Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, et al. In vitro and In vivo Inhibition of Helicobacter pylori by Lactobacillus casei Strain Shirota. Appl Environ Microbiol 2004; 70: 518-526.

17. Beessa L.J, Correia D.M, Cellini L, Azevedo N & Rocha I. Optimization of culture conditions to improve Helicobacter pylori growth in Ham's F-12 medium by response surface methodology. Int J Immunopathol Pharmacol  2012; 25:901-909.

18. Mobley HL, Cortesia MJ, Rosenthal L, Jones B. Characterization of urease from Campylobacter pylori. J Clin Microbiol 1988; 26: 831–836.

19. Mustafa S, Husaini A, Hipolito N, Hasnain H, Nurshikin S, Hairul AR. Application of Response Surface Methodology for Optimizing Process Parameters in the Production of Amylase by Aspergillus flavus NSH9 under Solid State Fermentation. Braz arch boil technol 2016; 59: 1-6.

20. Chen X, Liu XM, Tian F, Zhang Q, Zhang HP, Zhang H, et al. Antagonistic activities of lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells. JFST 2012;77 :9-14.

21. Ryan KA, Daly P, Li Y, Hooton C, O’Toole PW. Strain-specific inhibition of Helicobacter pylori by Lactobacillus salivarius and other lactobacilli. J Antimicrob Chemother 2008, 61:831–834.

22. Takeda S, Takeshita M, Matsusaki T, Kikuchi Y, Send-ayush C, Oyunsuren T, et al. In vitro and in vivo Anti-Helicobacter pylori Activity of Probiotics Isolated from Mongolian Dairy Products. JFST 2015; 21: 399-406.

23. Klerk N, Maudsdotter L, Gebreegziabher H, Saroj S, Eriksson B, et al. Lactobacilli Reduce Helicobacter pylori Attachment to Host Gastric Epithelial Cells by Inhibiting Adhesion Gene Expression. Infect Immun 2016; 84: 1526-1535.

24. McNulty CA, Lasseter G, Shaw I, Nichols T, D’Arcy S, Lawson AJ, et al. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther 2012; 35: 1221-1230.

25. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374–1384.

26. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010; 19:409-414.

27. Talebi Bezmin Abadi A, Ghasemzadeh A, Taghvaei T, Mobarez AM. Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran. Intern Emerg Med 2012; 7:447–452.

28. Khademi F, Poursina F, Hosseini E, Akbari M, Ghasemian H. Helicobacter pylori in Iran: A systematic review on the antibiotic resistance. Iran J Basic Med Sci 2015; 18: 2–7.

29. Saniee P, Hosseini F, Kadkhodaei S, Siavoshi F, Khalili-Samani S. Helicobacter pylori Multidrug Resistance Due to Misuse of Antibiotics in Iran. Arch Iran Med 2018; 21:283-288.

30. Zhang M, Qian W,Qin Y, He I, Zhou Y. Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis. World J Gastroenterol 2015; 21: 4345–4357.

31. Patel A, Shah N, Prajapati J.B. Clinical application of probiotics in the treatment of Helicobacter pylori infection-A brief review. J Microbiol Immu & infect 2014; 47: 429-437.

32. Matjaz H, Rok O. Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol 2015; 21: 10644–10653.

33. Losurdo G, Cubisino R, Barone M, Principi M, Leandro G, Ierardi E, et al. Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis. World J Gastroenterol 2018; 24: 139–149.

34. Francavilla R1, Polimeno L, Demichina A, Maurogiovanni G, Principi B, Scaccianoce G, et al. Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study. J Clin Gastroenterol 2014; 48: 407-413.

35. García A, Navarro K, Sanhueza E, Pineda S, Pastene E, Quezada M, et al. Characterization of Lactobacillus fermentum UCO-979C, a probiotic strain with a potent anti- Helicobacter pylori activity. Electronic J Biotechnology 2017; 25: 78-83.

36. Johnson-Henry K, Mitchell D, Avitzur Y, Galindo-Mata E, Jones NL, Sherman PM. Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig Dis Sci 2004; 49: 1095-1102.

37. Kasra-Kermanshahi R, Mobarak-Qamsari E. Inhibition effect of lactic acid bacteria against food born pathogen, Listeria monocytogenes. Appl Food Biotechnol 2015;2:11-19.

38. Pacifico L, Osborn J-F, Bonci E, Romaggioli S, Baldini R, Chiesa C. Probiotics for the treatment of Helicobacter pylori infection in childelen. World J Gastroenterol 2014;20:673-683.

39. Rutherford S, Bassler B. Bacterial Quorum Sensing: Its Role in Virulence and Possibilities for Its Control. Cold Spring Harb Perspect Med 2012; 2: pii: a012427.

40. Hathroubi S, Servetas SL, Windham I, Merrell DS, Ottemann KM. Helicobacter pylori Biofilm Formation and Its Potential Role in Pathogenesis. Microbiol Mol Biol Rev 2018; 9: 1-18.

41. Aiba Y, Suzuki N, Kabir MA, Takagi A, Koga Y. Lactic acid mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. World J Gastroenterol 1998; 11: 2097-2103.

42. Lin W, Wu C, Fang TJ, Guo J, Huang S, Lee M, et al. Anti-Helicobacter pylori activity of fermented milk with lactic acid bacteria. J Sci Food Agric 2011; 91: 1424-1431.

43. Ryan K.A, O'Hara A, Van Pijkeren J, Douillard F, O'Toole P. Lactobacillus salivarius modulates cytokine induction and virulence factor gene expression in Helicobacter pylori. J Med Microbiol 2009; 58: 996-1005,

44. Midolo PD, Lambert JR, Hull R, Luo F, Grayson ML. In vitro inhibition of Helicobacter pylori NCTC11637 by organic acids and lactic acid bacteria. J Appl Bacteriol 1995; 79:475–479.

45. Coconnier MH, Lievin V, Hemery E, Servin AL. Antagonistic activity against Helicobacter pylori infection in vitro and in vivo by human Lactobacillus acidophilus strain LB. Appl Environ Microbiol 1998; 64: 4573-4580.

46. Stingl K, Uhlemann E, Deckers-Hebestreit G, Schmid R, Bakker E, Altendorf K. Prolonged Survival and Cytoplasmic pH Homeostasis of Helicobacter pylori at pH 1. Infect Immun 2001; 69: 1178–1180.

47. Goudarzi L, Kasra Kermanshahi R, Moosavi-Nejad Z, Soltan Dalla M. Evaluation of Antimicrobial Activity of Probiotic Lactobacillus Strains against Growth and Urease Activity of Proteus spp. JMB 2017; 6:31-43.

48. Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 2002;32: 105-110.

49. Kabir AM, Aiba Y, Takagi A, Kamiya S, Miwa T, Koga Y. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut 1997; 41: 49-55.